Ainos, Inc. (AIMD) · Nov 20, 2026 · Delisting
Nasdaq deficiency — $1.72M equity vs $2.50M Nasdaq minimum
Ainos’ Nasdaq notice formalizes a listing-compliance problem: equity is below the required minimum, forcing a financing or debt-conversion plan.
Ainos is trying to turn AI Nose deployments in semiconductor and industrial settings, alongside VELDONA licensing, into a commercial business; its latest quarter showed higher revenue but the company remains loss-making and dependent on additional financing.
The listing problem is now formal, not hypothetical. Nasdaq says Ainos fails the $2.5 million stockholders’ equity requirement, with only $1.721 million reported at September 30, 2026. The company also says it fails the two alternative standards, removing the simplest paths to remain compliant.
| Measure | September 30, 2026 | Nasdaq requirement |
|---|---|---|
| Stockholders’ equity (Balance Sheet) | $1.72M | $2.50M |
| Estimated shortfall | $779K | — |
The immediate trading risk is limited, but the financing pressure is real. The notice does not immediately suspend trading, and Ainos has until January 4, 2027 to submit a recovery plan. But management is already considering converting debt into equity and pursuing other capital raises, which points to a need to repair the balance sheet before the business has generated enough operating strength to do so internally. 〔0〕 〔1〕
Most of the financial weakness was already visible in the recent 10-Q; the new information is the deadline and cure process. That makes this partly known rather than a surprise, but the formal Nasdaq notice converts a balance-sheet warning into a concrete listing-compliance test. There is no assurance Nasdaq accepts the plan, grants an extension, or that any financing can be completed on acceptable terms. 〔2〕
Bottom line: This does not delist Ainos today, but it confirms that the company’s commercialization story is now constrained by a balance-sheet and financing problem. The next meaningful test is whether it can present and execute a credible plan before the January 4 deadline.
Compliance plan due January 4, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!